Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

February 28, 2002

Study Completion Date

February 28, 2002

Conditions
Chronic Nonmalignant Pain
Interventions
DRUG

Buprenorphine transdermal patch

Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear

Trial Locations (19)

27103

ALL-TRIALS Clinical Research LLC, Winston-Salem

27262

Cornerstone Research Care, High Point

28211

The Arthritis Clinic, Charlotte

32720

University Clinical Research Deland, DeLand

33024

University Clinical Research Inc,, Pembroke Pines

33134

Clinical Research of South Florida, Coral Gables

33321

Gold Coast Research LLC, Tamarac

33324

Gold Coast Research, LLC, Plantation

33761

Tampa Bay Medical Research Inc, Clearwater

38119

Summit Research Solutions, Memphis

41017

Southeastern Center for Headache and Pain, Crestview Heights

47712

Family Medicine Associates, Evansville

47807

Pain Management & Rehabilitation, Terre Haute

49009

Westside Family Medical Center PC, Kalamazoo

53151

Clinical Research Management, New Berlin

78758

Radiant Research - Austin, Austin

84107

Wasatch Clinical Research, Salt Lake City

85023

Arizona Research Center Inc., Phoenix

06611

Clinical Research Consultants Inc, Trumbull

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT01151098 - Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study | Biotech Hunter | Biotech Hunter